☆ 4.7 Article

The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?

LEUKEMIA (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia

Hannah J. Uckelmann et al.

Summary: The dysregulation of developmental and stem cell-associated genes is a common phenomenon during cancer development. Most patients with acute myeloid leukemia (AML) express high levels of HOXA cluster genes and MEIS1, with an NPM1 mutation (NPM1c) being common in these cases. This study reveals that NPM1c directly binds to specific chromatin targets, collaborates with the MLL1 complex, and directly regulates oncogenic gene expression in AML.

CANCER DISCOVERY (2023)

Add to Collection

Review Hematology

NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions

Brunangelo Falini

Summary: The importance and relevance of NPM1 mutations in AML, including their involvement in chromatin-level regulation and gene expression, as well as their implications for classification and potential targeted therapies.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Ghayas C. Issa et al.

Summary: Targeting critical epigenetic regulators can reverse aberrant transcription in cancer and restore normal tissue function. In this study, we investigated the first-in-human phase 1 clinical trial of revumenib, a potent and selective oral inhibitor of the menin-KMT2A interaction, in patients with relapsed or refractory acute leukaemia. The therapy was associated with a low frequency of adverse events and a significant rate of complete or partial remission in the efficacy analysis population.

NATURE (2023)

Add to Collection

Article Multidisciplinary Sciences

MEN1 mutations mediate clinical resistance to menin inhibition

Florian Perner et al.

Summary: Chromatin-binding proteins are important regulators of cell state in haematopoiesis. Clinical trials have shown that the menin inhibitor revumenib can treat leukaemia with KMT2Ar or NPM1 mutations. However, acquired resistance to menin inhibition may be caused by somatic mutations in the MEN1 gene.

NATURE (2023)

Add to Collection

Review Immunology

Intracellular Antibodies for Drug Discovery and as Drugs of the Future

T. H. Rabbitts

Summary: The application of antibodies in cells, particularly intracellular antibodies, has expanded over the years. These antibodies, including fragments, can be used to perturb protein activity within cells and elicit intracellular responses. They are not only research tools, but also have potential applications as drugs and templates for drug discovery. Their ability to discriminate between closely related proteins adds a new dimension to drug screening and development.

ANTIBODIES (2023)

Add to Collection

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber et al.

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.

BLOOD (2022)

Add to Collection

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Joseph D. Khoury et al.

Summary: This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms, emphasizing the refinement of diagnostic criteria and the importance of actionable biomarkers, while maintaining global applicability.

LEUKEMIA (2022)

Add to Collection

Article Hematology

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML

Giulia Pianigiani et al.

Summary: NPM1 is the most frequently mutated gene in adults with acute myeloid leukemia (AML). The interaction between mutant NPM1 (NPM1c) and exportin-1 (XPO1) causes aberrant cytoplasmic dislocation of NPM1c and promotes high expression of homeobox (HOX) genes. However, the current dosing frequency and efficacy of drugs against NPM1-mutated AML are limited. The second-generation XPO1 inhibitor eltanexor, with a higher dosing frequency, can induce sustained downregulation of HOX genes, induce terminal AML differentiation, and prolong the survival of patients, providing important information for the design of clinical trials.

BLOOD ADVANCES (2022)

Add to Collection

Meeting Abstract Hematology

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba et al.

BLOOD (2022)

Add to Collection

Review Oncology

Therapeutic implications of menin inhibition in acute leukemias

Ghayas C. Issa et al.

Summary: Menin inhibitors are novel targeted agents currently being developed for the treatment of genetically defined subsets of acute leukemia, showing promising early results in specific leukemia types, such as NPM1 mutations. These inhibitors target various gene regulatory roles of menin in leukemogenesis and are being investigated in clinical studies for relapsed acute leukemias.

LEUKEMIA (2021)

Add to Collection

Review Hematology

NPM1-mutated acute myeloid leukemia: from bench to bedside

Brunangelo Falini et al.

BLOOD (2020)

Add to Collection

Article Biology

Chromatin-bound CRM1 recruits SET-Nup214 and NPM1c onto HOX clusters causing aberrant HOX expression in leukemia cells

Masahiro Oka et al.

ELIFE (2019)

Add to Collection

Article Oncology

Mutant NPM1 Maintains the Leukemic State through HOX Expression

Lorenzo Brunetti et al.

CANCER CELL (2018)

Add to Collection

Article Multidisciplinary Sciences

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment

Camilo E. Quevedo et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article Oncology

Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia

Michael W. M. Kuhn et al.

CANCER DISCOVERY (2016)

Add to Collection

Article Hematology

A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias

Alicja M. Gruszka et al.

BLOOD (2010)

Add to Collection

Review Oncology

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications

B. Falini et al.

LEUKEMIA (2009)

Add to Collection

Article Biochemistry & Molecular Biology

Structural Consequences of Nucleophosmin Mutations in Acute Myeloid Leukemia

Charles G. Grummitt et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2008)

Add to Collection

Article Biotechnology & Applied Microbiology

Structure-based maximal affinity model predicts small-molecule druggability

Alan C. Cheng et al.

NATURE BIOTECHNOLOGY (2007)

Add to Collection

Article Hematology

Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance

M Alcalay et al.

BLOOD (2005)

Add to Collection

Article Medicine, General & Internal

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

B Falini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Biochemistry & Molecular Biology

Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation

T Tanaka et al.

EMBO JOURNAL (2003)

Add to Collection

Article Biochemistry & Molecular Biology

Mapping the functional domains of nucleolar protein B23

K Hingorani et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.